Argos’ management team and Board of Directors have extensive experience with both the science and business of biotechnology, ranging from preclinical to clinical development, product launch and marketing, to manufacturing commercial products.
Lee F. Allen, M.D., Ph.D. – Chief Medical Officer
Lee F. Allen, M.D., Ph.D., has served as our Chief Medical Officer since January 2016. Prior to joining Argos, Dr. Allen served as Chief Medical Officer at Spectrum Pharmaceuticals, a commercial stage biotechnology company focused on Hematology/Oncology since March 2013. Prior to joining Spectrum, Dr. Allen held executive level positions with AMAG Pharmaceuticals from August 2007 until March 2013, most recently serving as Chief Medical Officer and Executive Vice President, Medical Development. Prior to that, Dr. Allen served as Cambridge Site Head and Vice President of Oncology Clinical Research & Development, Wyeth Research from April 2003 until August 2007. In addition, he has also held executive positions in Pfizer and BASF’s Knoll Pharmaceuticals Hematology/Oncology groups. In addition, Dr. Allen has served in clinical leadership roles in the Division of Hematology/Oncology at the University of Utah Health Sciences’ Huntsman Cancer Institute and Duke University Medical Center. He holds a Ph.D. in pathology and an M.D. from the University of Medicine and Dentistry of New Jersey, and trained in Internal Medicine and Hematology/Oncology at the Duke University Medical Center.
Lori R. Harrelson, C.P.A. – Vice President, Finance
Lori R. Harrelson has served as our Vice President of Finance since July 2011. Ms. Harrelson served as our Director of Finance and Accounting from January 2007 to July 2011 and as our Director of Accounting and Financial Reporting from September 2004 to January 2007. Prior to joining us, Ms. Harrelson served as Finance Manager at LipoScience, Inc., a diagnostic company, from 2001 to 2004. Ms. Harrelson received a B.S. in finance from East Carolina University and is a C.P.A.
Richard D. Katz, M.D., M.B.A. – Chief Financial Officer
Dr. Katz comes to Argos with more than 20 years of experience in healthcare finance and corporate development. Most recently, Dr. Katz served as chief financial officer for Viamet Pharmaceuticals, Inc. Previously, Dr. Katz served as chief financial officer for Icagen, Inc., where he was instrumental in the company’s initial public offering and subsequent financings, the formation of several strategic collaborations, and the company’s sale to Pfizer. Prior to Icagen, Dr. Katz worked as a vice president in the healthcare group at Goldman, Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions, and corporate restructurings. Dr. Katz received his A.B. magna cum laude from Harvard University, his M.D. from the Stanford University School of Medicine and his M.B.A. from Harvard Business School, where he graduated as a Baker Scholar.
John D. Menditto – Vice President, Corporate Communications and Investor Relations
John D. Menditto has served as Vice President of Corporate Communications and Investor Relations since May 2015. Prior to joining us, he spent a number of years as a communications consultant, including, more recently, as Head of Investor Relations, The Americas, at the Imagination Group. He served as Director, Investor Relations in North America at Novartis Corporation, from 2001 until 2008 and Senior Global Director of Investor Relations at Medco Health Solutions, from 2008 until 2009. He holds a B.A. in public relations from Susquehanna University in Selinsgrove, Pennsylvania.
Charles A. Nicolette, Ph.D. – Chief Scientific Officer and VP, Research and Development
Charles A. Nicolette, Ph.D. has served as our Chief Scientific Officer since December 2007 and as our Vice President of Research and Development since December 2004. Dr. Nicolette served as our Vice President of Research from July 2003 to December 2004. Prior to joining us, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, from 1997 to 2003, most recently as Director of Antigen Discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.
Joan C. Winterbottom – Vice President and Chief Human Resources Officer
Joan C. Winterbottom, has served as our Chief Human Resources Officer since February 2015. Prior to joining Argos Therapeutics she served as Senior Vice President, Human Resources at Amicus Therapeutics, Inc., from 2012 to 2014 and as Senior Vice President, Human Resources at Savient Pharmaceuticals, Inc., from 2011 to 2012. Earlier Ms. Winterbottom held human resources leadership roles at Johnson & Johnson from 2001 to 2011, most recently as Vice President of Human Resources for the Global Over-the-Counter/Nutritionals/Wellness and Prevention global business unit and before that as Vice President of Human Resources for J&J’s McNeil Consumer Healthcare Company. She also served as Global Director, Head of Human Resources for the J&J Biologics, Immunology, and Oncology Research & Development unit, Centocor. Ms. Winterbottom earned a B.S. in business and economics from Lehigh University, and a graduate level certificate in organization development from Saint Joseph’s University.
Charles Drake, M.D., Ph.D.
Dr. Drake earned his MD / PhD degree in immunology from the National Jewish Center for Immunology in Colorado. He is board-certified in medical oncology and is currently a professor of medical oncology, immunology, and urology at the Johns Hopkins Kimmel Cancer Center. Dr. Drake also serves as the co-director of the division of immunology within the department of oncology. His laboratory and clinical research focuses on understanding the immune response to GU cancers, and using that information to design informative translational clinical trials.
Robert Figlin, M.D., FACP
Dr. Figlin is board-certified in medical oncology and internal medicine and is currently the principal investigator for the pivotal phase 3 ADAPT clinical trial of AGS-003. He is professor of medicine and biomedical sciences at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and holds the Steven Spielberg Family chair in hematology oncology. Dr. Figlin earned his MD from the Medical College of Pennsylvania and is a fellow of the American College of Physicians and the International Society for Biologic Therapy, as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the National Comprehensive Cancer Center Network and the American Urological Association.
Bernard Fox, Ph.D.
Dr. Fox earned his PhD at Wayne State University and has been chief of the laboratory of molecular and tumor immunology at the Earle A. Chiles Research Institute since 1994. He also serves as member of the Knight Cancer Institute and associate professor for the department of molecular microbiology and immunology at the Oregon Health Sciences University and is an ambassador and past president of the Society for Immunotherapy of Cancer (SITC) and current chair of the World Immunotherapy Council. He also serves on the steering committee for the SITC-led global immunoscore task force and previously served as a steering committee member for the SITC-FDA task force on immunotherapy biomarkers in cancer.
Gerald Linette, M.D., Ph.D.
Dr. Linette earned his MD/PhD in microbiology from Georgetown University School of Medicine and is currently associate professor of medicine and neurosurgery, division of oncology at the Washington University School of Medicine in St. Louis. A diplomat of medical oncology with the American Board of Internal Medicine, he also serves as medical director, melanoma service at the Siteman Cancer Center. Dr. Linette is a member of the American Society of Clinical Oncology, American Society of Hematology, American Association of Immunologists, and American Association for Cancer Research. His primary interest is human cancer immunology.
Thomas Schwaab, M.D., Ph.D.
Dr. Schwaab is board-certified in urology and joined the Roswell Park Cancer Institute faculty in 2009 where he currently serves as chief of strategy, business development and outreach and associate professor of oncology. An expert in immunotherapy for bladder, prostate and kidney cancers, Dr. Schwaab earned his MD and PhD from Medizinische Hochscule Hannover in Germany.
Robert Seder, M.D.
Dr. Seder earned his MD at Tufts University and is currently chief of the cellular immunology section, Vaccine Research Center, at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. He has also served as chief of the clinical immunology section in the laboratory of clinical investigation, part of the NIAID Division of Intramural Research. Dr. Seder’s research is focused on developing and understanding how vaccines mediate protective antibody and T cell immunity against HIV, malaria and tuberculosis.
Jeffrey D. Abbey, M.B.A., J.D.
Jeffrey D. Abbey has served as our President and Chief Executive Officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010, including as our Vice President of Business Development from February 2004 to January 2009 and as our Chief Business Officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.
Hubert Birner, Ph.D., M.B.A. – Chairman of the Board
Hubert Birner, Ph.D. has served as the Chairman of our board of directors since 2005 and a member of our board of directors since 2001. Dr. Birner joined the Munich office of TVM Capital, a venture capital firm and affiliate of Argos, as an investment manager in 2000 and currently serves as the Managing Partner of the firm. From 1998 to 2000, Dr. Birner served as head of European business development and director of marketing for Germany at Zeneca Agrochemicals, a biopharmaceutical company. Prior to joining Zeneca Agrochemicals, Dr. Birner served as a management consultant in McKinsey & Company´s European healthcare and pharmaceutical practice. Dr. Birner currently serves on the board of directors of Proteon Therapeutics, Inc. and SpePharm Holdings BV. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG and Jerini AG. Dr. Birner received an M.B.A. from Harvard Business School and a doctorate in biochemistry from Ludwig-Maximilians University in Munich, Germany. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.
Robert F. Carey
Robert Carey has been a member of the board of directors since September 2015. Mr. Carey is Executive Vice President and Chief Business officer at Horizon Pharma plc. From 2003 to 2014, Mr. Carey was Managing Director and head of healthcare investment banking at JMP Securities LLC. Prior to that, Mr. Carey held various senior positions at several investment banking firms, including Dresdner Kleinwort Wasserstein, Inc., Prudential Securities Incorporated, Vector Securities International, Inc., and Shearson Lehman Hutton Inc. He has served as an advisor on greater than $15 billion in financings, as well as numerous mergers and acquisitions. He is a member of the board of directors for Red Hen Corporation, Hawthorne Race Course, Inc., and Suburban Downs, Inc. He is also a former member of the board of directors for the Illinois Biotechnology Industry Organization (iBIO). Mr. Carey holds a BBA in accounting from the University of Notre Dame.
Igor Krol has been a member of the board of directors since June 2016. Mr. Krol is currently CEO of Veset International Ltd. (Veset), a technology start-up focused on bringing innovative cloud technologies to media and broadcasting industry. Prior to joining Veset, Mr. Krol spent several years in investment banking at Sberbank CIB and Citigroup Investment Banking. During his time at Citigroup, Mr. Krol worked with a broad range of global and emerging markets clients focusing on M&A and capital markets deal origination and execution including the initial public offering for Pharmstandard, the leading Russian pharmaceutical company. Mr. Krol still maintains an advisory role with Pharmstandard. Prior to those roles, Mr. Krol worked at Nestle, the leading global consumer company in varying roles including finance and purchasing.
Mr. Krol holds an MBA degree from INSEAD, Fontainebleau, France, and BA in Systems Engineering from MIREA Technical University, Moscow, Russia.
Andrei Petrov, Ph.D.
Andrei Petrov, Ph.D. has served as a member of our board of directors since August 2013. Dr. Petrov has been the Chief Scientific Officer of International Biotechnology Center Generium, a private scientific research and drug development company, since 2011, and the Chief Executive Officer of CJSC ‘Kollectsiya,’ a venture investment company, since 2013. From 2008 to 2011, Dr. Petrov served as Senior Scientist at CJSC Masterclone, a drug discovery and development company. Dr. Petrov has also served as a member on the board of directors of Affitech A/S since 2010, and as a member on the board of directors of co.don AG since 2012.
Sander Van Deventer, M.D. Ph.D.
Sander van Deventer, M.D., Ph.D. has served as a member of our board of directors since 2001. Dr. van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a General Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), Uniqure (Amsterdam, The Netherlands), Cardoz (Stockholm, Sweden) gICare (Montreal, Canada) en Hookipa (Vienna, Austria).
Dr. van Deventer was trained as an internist and board vertified gastroenterologist, received doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. He has authored more than 500 peer review scientific papers, and supervised more than 40 PhD students.
Philippe Van Holle
Philippe Van Holle held the position of Senior VP Global Human Resources at Celgene Corporate HQ in Summit, New Jersey until October, 2014. From January 1, 2012 until December 2012, Philippe Van Holle held the position of Chairman International in Celgene. He was President EMEA since November 2008, after building the European organization as Head of Europe since January 2006. Mr. Van Holle, of Belgian nationality, served as Vice President Northern Europe for the Genzyme Corporation from September 2001 to December 2005. Previously, Mr. Van Holle had been Vice President Global Marketing at Baxter International, for the Renal Division, which he joined in 1998. He was Vice President Marketing, Amgen Europe since 1989. He received his undergraduate degree in Econometrics at the Antwerp University St. Ignatius, Belgium in 1976 and a M.B.A from the Cornell University, Ithaca, NY.